{"id":"W3124365819","doi":"10.1111/pcmr.12960","title":"First‐line atezolizumab monotherapy in patients with advanced <i>BRAF</i><sup>V600</sup> wild‐type melanoma","year":2021,"lang":"en","type":"article","venue":"Pigment Cell & Melanoma Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Atezolizumab; Internal medicine; Pembrolizumab; Adverse effect; Melanoma; Oncology; Gastroenterology; Cohort; Response Evaluation Criteria in Solid Tumors; Surgery; Progressive disease; Cancer; Disease; Cancer research; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000460289,0.0002340669,0.0008032033,0.0001532739,0.0001718709,0.0003986687,0.000171311,0.0003700056,0.001165845],"category_scores_gemma":[0.0006483736,0.0001664579,0.000486959,0.0002151438,0.00009938257,0.0003062951,0.0001201441,0.0007703365,0.000260416],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004202378,"about_ca_system_score_gemma":0.0005812525,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007901577,"about_ca_topic_score_gemma":0.002460378,"domain_scores_codex":[0.9998473,0.00005715884,0.000012693,0.00003459333,0.00002140331,0.00002682484],"domain_scores_gemma":[0.999701,0.00007706457,0.00007677504,0.00001336222,0.00002613647,0.0001057579],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1496258,0.008571572,0.4837663,0.001256388,0.001968707,0.001351596,0.0004317332,0.002983485,0.0472104,0.0002622444,0.02027272,0.2822992],"study_design_scores_gemma":[0.05691122,0.1515349,0.7550085,0.00037668,0.001719146,0.002935127,0.0003505917,0.007780858,0.006301062,0.0004646152,0.01653399,0.00008336222],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9925015,0.004330847,0.0002116835,0.000346476,0.00005939045,0.000153479,0.0008792575,0.00003259298,0.001484796],"genre_scores_gemma":[0.9973801,0.0009005461,0.0002283191,0.0003187995,0.00004415463,0.00008292418,0.0007059029,0.000004121239,0.0003351987],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001165845,"threshold_uncertainty_score":0.003900111,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03026515582306657,"score_gpt":0.3172720341146936,"score_spread":0.287006878291627,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}